Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 311 to 320 of 1345 total matches.

Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
stability against beta-lactamases.4,5 SPECTRUM OF ACTIVITY — Cefiderocol has no clinically relevant ...
The FDA has approved cefiderocol (Fetroja – Shionogi), a new IV cephalosporin antibiotic, for treatment of complicated urinary tract infections (UTI) caused by susceptible gram-negative bacteria in adults who have limited or no alternative treatment options.
Med Lett Drugs Ther. 2020 May 4;62(1597):65-8 |  Show IntroductionHide Introduction

Pharmaceutical Drug Overdose

   
Treatment Guidelines from The Medical Letter • Sep 01, 2006  (Issue 49)
pneumonia. Perforation of the esophagus, laryngospasm and hypoxia can occur. Activated charcoal (AC ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
Treat Guidel Med Lett. 2006 Sep;4(49):61-6 |  Show IntroductionHide Introduction

Timing of Remdesivir for COVID-19

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
analog that inhibits viral replication by binding to RNA-dependent RNA polymerase. It is active against ...
Remdesivir (Veklury – Gilead), an investigational antiviral drug administered by IV infusion, is now available through an FDA Emergency Use Authorization (EUA) for treatment of COVID-19 in all hospitalized patients. An earlier EUA limited use of the drug to patients hospitalized with severe disease.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):161 |  Show IntroductionHide Introduction

In Brief: Anktiva for Bladder Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Jun 24, 2024  (Issue 1705)
of the drug to its receptor causes proliferation and activation of natural killer (NK) and CD8+ killer ...
Nogapendekin alfa inbakicept-pmln (Anktiva – ImmunityBio), a first-in-class interleukin-15 (IL15) receptor agonist, has been approved by the FDA for use with Bacillus Calmette-Guérin (BCG) for treatment of patients with BCG-unresponsive nonmuscle invasive bladder cancer (NMIBC) with carcinoma in situ with or without papillary tumors. Such patients generally undergo bladder tumor resection, followed by intravesical BCG treatment, but treatment failure and cancer recurrence are common. The adenoviral vector-based intravesical gene therapy nadofaragene firadenovec-vncg (Adstiladrin)...
Med Lett Drugs Ther. 2024 Jun 24;66(1705):e105-6   doi:10.58347/tml.2024.1705e |  Show IntroductionHide Introduction

Antiviral Drugs

   
Treatment Guidelines from The Medical Letter • Mar 01, 2013  (Issue 127)
acyclovir therapy (400 mg three times daily) beginning at week 36 to pregnant women with active recurrent ...
The drugs of choice for treatment of viral infections (other than HIV) and their dosages are listed in Tables 1-6 on the pages that follow. Some of the indications and dosages recommended here have not been approved by the FDA. Vaccines used for the prevention of viral infections are discussed elsewhere.
Treat Guidel Med Lett. 2013 Mar;11(127):19-30 |  Show IntroductionHide Introduction

Olsalazine

   
The Medical Letter on Drugs and Therapeutics • Nov 16, 1990  (Issue 831)
available in the USA. PHARMACOLOGY — 5-ASA is active topically in the colon, but not systemically. Given ...
Olsalazine sodium (Dipentum - Pharmacia), a dimer (two molecules linked by an azo bond) of 5-aminosalicylic acid, was recently approved by the US Food and Drug Administration for oral use to maintain remission of ulcerative colitis in adult patients who cannot tolerate sulfasalazine (Azulfidine; and others).
Med Lett Drugs Ther. 1990 Nov 16;32(831):105-6 |  Show IntroductionHide Introduction

Gabapentin - A New Anticonvulsant

   
The Medical Letter on Drugs and Therapeutics • Apr 29, 1994  (Issue 921)
with antiepileptic activity are generally tried first for this indication. PREVIOUSLY AVAILABLE DRUGS ...
Gabapentin (Neurontin - Parke-Davis), a cyclohexane acetic acid derivative, has been approved by the US Food and Drug Administration for use in addition to other antiepileptic drugs in patients with partial (focal) seizures with or without secondary generalization. Since this diagnostic category includes the largest number of patients with intractable epilepsy, new drugs with antiepileptic activity are generally tried first for this indication.
Med Lett Drugs Ther. 1994 Apr 29;36(921):39-40 |  Show IntroductionHide Introduction

Treatment of Hypothermia

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 1994  (Issue 938)
. Hypothermia associated with exhaustion during outdoor sports activities can occur even at relatively mild ...
This winter physicians in many area may see patients suffering from hypothermia. Old age, lack of adequate housing, drug overdose and alcohol ingestion are often prediposing factors, but hypothermia also occurs in healthy young people after prolonged exposure to cold due to incapacitating trauma or cold water immersion. Hypothermia associated with exhaustionduring outdoor sports activities can occur even at relatively mild temperatures.
Med Lett Drugs Ther. 1994 Dec 23;36(938):116-7 |  Show IntroductionHide Introduction

Two New Retinoids for Psoriasis

   
The Medical Letter on Drugs and Therapeutics • Nov 07, 1997  (Issue 1013)
), an acetylenic retinoid prodrug, is rapidly converted to its active form, tazarotenic acid. Both compounds appear ...
The US Food and Drug Administration (FDA) has approved two new retinoids for treatment of psoriasis. Tazarotene gel 0.05% and 0.1% (Tazorac - Allergan) is being marketed for topical use in patients with stable, mild to moderate plaque psoriasis. Acitretin (Soriatane - Roche) is being promoted for systemic use in severe psoriasis.
Med Lett Drugs Ther. 1997 Nov 7;39(1013):105-6 |  Show IntroductionHide Introduction

Celecoxib for Arthritis

   
The Medical Letter on Drugs and Therapeutics • Jan 29, 1999  (Issue 1045)
inhibits the activity of CYP2D6 and therefore might increase serum concentrations of drugs metabolized ...
Celecoxib, a selective COX-2 inhibitor, has been approved by the FDA for treatment of osteoarthritis and rheumatoid arthritis.
Med Lett Drugs Ther. 1999 Jan 29;41(1045):11-2 |  Show IntroductionHide Introduction